Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 19/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698570 | 0.87 | NAMPT (0.92) | NAMPTNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3700311 | 0.87 | NAMPT (0.92) | NAMPTNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3704207 | 0.85 | NAMPT (0.71) | NAMPTNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3706543 | 0.85 | NAMPT (1.00) | NAMPT | |
| SCHEMBL3706158 | 0.84 | NAMPT (0.74) | NAMPTNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3706405 | 0.84 | NAMPT (0.70) | NAMPTNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3701542 | 0.84 | NAMPT (0.84) | NAMPT | |
| SCHEMBL5518620 | 0.83 | RAB9A (0.68) | NAMPTNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3710712 | 0.83 | NAMPT (0.70) | NAMPTNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3704018 | 0.82 | NAMPT (1.00) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | claimed |
| EP-2640704-A1 | NAMPT INHIBITORS | Abbvie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067963-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122924-A1 | NAMPT INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122924-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885NPC1 88/4885ALDH1A1 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.